Neoadjuvant Immunochemotherapy Increases the Abundance of Tertiary Lymphoid Structures and Lymphocyte Subpopulations Is Associated With Prognosis of Esophageal Squamous Cell Carcinoma
Cancer Medicine · 2026
DOI: 10.1002/cam4.71889 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Ning Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The First Hospital of Shanxi Medical University, Taiyuan, China. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Tertiary Lymphoid Structures, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Young Investigator Grant in Beijing You'an Hospital Affiliated to Capital Medical University (BJYAYY-YN2024-09).
Abstract (Originalsprache)
Neoadjuvant immunochemotherapy (NIC) has emerged as a promising strategy for esophageal squamous cell carcinoma (ESCC). However, its impact on tertiary lymphoid structures (TLSs) and the immune microenvironment remains to be fully elucidated. We retrospectively analyzed 50 ESCC patients treated with NIC ( n = 25) or chemotherapy alone ( n = 25) between 2021 and 2023. TLSs and lymphocyte subpopulations in paired tumor tissues were assessed via multiplex immunofluorescence. Disease‐free survival (DFS) was evaluated using Cox regression, and correlations with peripheral blood lymphocytes were analyzed. NIC significantly increased the abundance and maturity of TLSs compared to chemotherapy alone. Specifically, NIC‐induced TLSs were enriched with CD3 + CD8 + PD‐1+ T cells and CD103 + CXCL13+ dendritic cells (DCs). Clinically, the NIC group demonstrated a significantly prolonged median DFS compared to the chemotherapy group (17.4 vs. 13.5 months, p = 0.009). High abundance of mature TLSs was an independent predictor of improved DFS (HR = 0.45). Furthermore, elevated proportions of CD3 + CD8 + PD‐1+ T cells and CD103 + CXCL13+ DCs within TLSs were strongly associated with longer survival. These local TLS alterations also correlated with specific changes in peripheral blood lymphocyte subsets. Our preliminary data suggest that NIC promotes TLS maturation and is associated with enrichment of specific immune subsets within TLSs. CD3 + CD8 + PD‐1+ T cells and CD103 + CXCL13+ DCs may serve as exploratory biomarkers associated with prognosis and immunotherapy response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, The First Hospital of Shanxi Medical University, Taiyuan, China.
- The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
- Shanxi Medical University, Taiyuan, China.
- Department of Medical Oncology, Beijing Youan Hospital, Capital Medical University, Beijing, China.
- Department of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Förderung
- Young Investigator Grant in Beijing You'an Hospital Affiliated to Capital Medical University (BJYAYY-YN2024-09)
Zitieren
APA
Li, N., Zhang, X., Tang, X., Shen, J., Qi, Q., Wu, H., Zhao, Y., & Wang, S. (2026). Neoadjuvant Immunochemotherapy Increases the Abundance of Tertiary Lymphoid Structures and Lymphocyte Subpopulations Is Associated With Prognosis of Esophageal Squamous Cell Carcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.71889
Vancouver
Li N, Zhang X, Tang X, Shen J, Qi Q, Wu H, et al. Neoadjuvant Immunochemotherapy Increases the Abundance of Tertiary Lymphoid Structures and Lymphocyte Subpopulations Is Associated With Prognosis of Esophageal Squamous Cell Carcinoma. Cancer Medicine. 2026. doi:10.1002/cam4.71889
BibTeX
@article{Li2026,
author = {Li, Ning and Zhang, Xiaoyan and Tang, Xupeng and Shen, Juanning and Qi, Qing and Wu, Huili and Zhao, Yuze and Wang, Shuo},
title = {Neoadjuvant Immunochemotherapy Increases the Abundance of Tertiary Lymphoid Structures and Lymphocyte Subpopulations Is Associated With Prognosis of Esophageal Squamous Cell Carcinoma},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.71889}
}
EUVIMED